We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Caisson Establishes Partnership with CordenPharma

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Caisson Biotech, LLC (Caisson) has announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma). Caisson has demonstrated successful technology transfer and cGMP scale-up with its corporate pharmaceutical partners utilizing its patented heparosan-based half-life extension and drug delivery platform, HEPtune®, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material.

As a manufacturer of the HEPtune® technology, CordenPharma will bring experience and expertise in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glycoconjugates, which are an integral component of its Peptides, Lipids & Carbohydrates technology platform offering.

“We are excited to announce a manufacturing relationship with CordenPharma,” said Breca Tracy, PhD, Vice President and Managing Director of Caisson. “CordenPharma’s experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate Caisson’s capabilities to fulfill requests for larger quantities of quality material for pre-clinical and clinical studies.”

Mimoun Ayoub, PhD, Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, CordenPharma International said, “We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma’s Peptides, Lipids & Carbohydrates platform, and we look forward to supporting Caisson Biotech’s partners as they develop and commercialize novel, life-saving therapeutics.”